GME vs GSK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 07, 2026

GME

48.4
AI Score
VS
GSK Wins

GSK

53.4
AI Score

Investment Advisor Scores

GME

48score
Recommendation
HOLD

GSK

53score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric GME GSK Winner
Forward P/E 28.2486 19.084 GSK
PEG Ratio 0.3059 95.4001 GME
Revenue Growth 14.1% 5.3% GME
Earnings Growth 633.3% -69.5% GME
Tradestie Score 48.4/100 53.4/100 GSK
Profit Margin 20.4% 14.5% GME
Beta 1.00 1.00 Tie
AI Recommendation HOLD BUY GSK

Relative Price Performance (Last 90 Days)

GME 1M: -0.4% · 3M: -12.1% GSK 1M: -4.4% · 3M: -3.2%

Current Technical Phase

GME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.6 · Price: $19.16

GSK

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 43

RSI (14): 42.9 · Price: $49.89

Fundamentals Snapshot

Metric GME GSK
Market Cap
Forward P/E 23.7 10.0
Trailing P/E 14.4 16.0
Revenue (TTM)
Revenue Growth 0.1% 0.1%
Gross Margin 0.3% 0.7%
Operating Margin 0.2% 0.3%
EPS 1.34 3.18
Dividend Yield 0.04%

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.